<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2-5179-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VIBERZI 100 MG FILM COATED TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ELUXADOLINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        238.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Patheon Pharmaceuticals Inc. " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Patheon Pharmaceuticals Inc. 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ALLERGAN PHARMACEUTICALS LTD
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A07DA06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Viberzi is a medicine that contains the active substance eluxadoline. It is used to treat irritable bowel syndrome (&lsquo;IBS&rsquo;) with diarrhoea (IBS-D) in adults.</p><p>IBS is a common gut disorder. The main symptoms of IBS-D include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach ache;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach discomfort;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urgent bowel movements.</p><p>Viberzi acts on the surface of your gut to restore the normal function of your bowels and block the sensation of pain and discomfort in IBS-D patients</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Viberzi:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to eluxadoline or any of the other ingredients of this medicine (listed in section 6);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have, or have had, pancreatitis (inflammation of the pancreas);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you don&rsquo;t have a gallbladder by birth or your gallbladder has been surgically removed;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have, or have had, problems with alcohol abuse, alcohol addiction, or if you drink alcohol in excess;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have, or have had, any blockage in your gallbladder, bile ducts, or pancreas;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have, or have had, disease or dysfunction of the sphincter of Oddi (a small round muscle in your upper belly that controls the flow of bile and pancreatic fluids into your upper intestine);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver disease with decreased liver function;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had constipation for a while or if constipation is the main symptom of your IBS (called &lsquo;IBS with constipation&rsquo; [IBS-C]);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have, or may have, a blockage in your intestine/bowels;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take medicines that may increase the level of the concentration of eluxadoline in the blood (so-called OATP1B1 inhibitor, e.g. ciclosporin).</p><p>Talk to your doctor or pharmacist if you are unsure if any of the above apply to you.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Stop taking Viberzi and seek medical attention immediately if you develop any of the following while taking this medicine:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; new or worsening pain in the belly, with or without nausea and vomiting;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; pain may begin soon after you start Viberzi. You may feel pain on the right side of your belly or the upper area of the belly, right below the ribs. The pain may feel like it is moving through to your back or shoulder;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; these symptoms are uncommon and may indicate pancreas or bile duct system problems</p><p>inflammation of the pancreas or spasm of the sphincter of Oddi.</p><p>o&nbsp;&nbsp; your risk of developing pancreas or bile duct system problems may be higher if you drink alcohol in excess,</p><p>o&nbsp;&nbsp; the spasm of the sphincter of Oddi usually goes away when you stop Viberzi.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation lasting longer than 4 days.</p><p>Please report to your doctor:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; how much alcohol you drink (e.g. daily number of drinks);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience any effects, such as dizziness and sleepiness.</p><p>Take special care if you are 65 years of age or older, as there is a higher risk that you may have certain side effects (see section 4).</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Viberzi should not be given to children and adolescents less than 18 years old as there is no information about its use in this age group.</p><p>&nbsp;</p><p><strong>Other medicines and Viberzi</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Avoid frequent use of loperamide (a medicine used to treat diarrhoea) if you are taking Viberzi as this may increase the risk of constipation. Avoid taking Viberzi with any other medicines that may cause constipation such as opioids (e.g. fentanyl [used to treat pain]) or anticholinergics (e.g. atropine [used to treat cardiac disorders among other indications]).</p><p>&nbsp;</p><p>Some medicines may increase the level of Viberzi in the blood. These medicines can include:</p><p>-&nbsp; ciclosporin (immunosuppressant used to reduce inflammation);</p><p>-&nbsp; gemfibrozil (used to lower lipid levels);</p><p>-&nbsp; atazanavir, lopinavir, ritonavir, saquinavir, tipranavir (antiretrovirals used to treat HIV);</p><p>- rifampicin (antibiotic used to treat infections).</p><p>&nbsp;</p><p>Do not take Viberzi with any of these medicines:</p><p>Viberzi may increase the level of some medicines in the blood. These medicines can include<strong>:</strong></p><p>-&nbsp; rosuvastatin (statin used to treat high cholesterol and to prevent cardiovascular disease);</p><p>-&nbsp; valsartan and olmesartan (used to treat high blood pressure);</p><p>-&nbsp; erythromycin (used to treat infections);</p><p>-&nbsp; midazolam (a medicine to sedate you when you e.g. undergo endoscopic procedures);</p><p>-&nbsp; nifedipine (used to treat high blood pressure);</p><p>-&nbsp; alfentanil, fentanyl (opioid analgesic used to treat pain);</p><p>-&nbsp; dihydroergotamine, ergotamine (used to treat migraine);</p><p>-&nbsp; pimozide (used to treat mental disorders) ;</p><p>-&nbsp; quinidine (used to treat heart diseases);</p><p>-&nbsp; sirolimus, tacrolimus (immunosuppressant used for the control of body&rsquo;s immune response).</p><p>If any of the above applies to you, tell your doctor or pharmacist before taking Viberzi. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>should not be taken whilst pregnant or breast-feeding. If you are pregnant or breast-feeding or you think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>It is unlikely that Viberzi will affect your ability to drive or use tools or machines. However, you may experience side effects such as sleepiness or dizziness while taking Viberzi which might affect your ability to drive or use machines. Do not drive or use machines while taking this medicine until you know how it affects you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>The recommended dose is one 100 mg tablet twice a day.</p><p>The tablets should be taken orally with food in the morning and in the evening.</p><p>&nbsp;</p><p><strong>If you take more Viberzi than you should</strong></p><p>If you have taken more Viberzi than you should, tell your doctor or seek urgent medical assistance.</p><p>&nbsp;</p><p><strong>If you forget to take Viberzi</strong></p><p>Do not take a double dose to make up for a forgotten dose. Take the next dose at the next scheduled time and continue as normal.</p><p>&nbsp;</p><p><strong>If you stop taking Viberzi</strong></p><p>Do not stop taking Viberzi without first talking to your doctor as your symptoms may worsen.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Some side effects can be serious</strong></p><p>Stop taking Viberzi , and seek medical attention immediately if you have new or worsening stomach pain, with or without nausea and vomiting, while taking Viberzi. These symptoms occur uncommonly (may affect up to 1 in 100 people) and may indicate pancreas or bile duct system problems (e.g. inflammation of the pancreas or spasm of the sphincter of Oddi).</p><p>&nbsp;</p><p><strong>Other side effects can include</strong></p><p>Common: may affect up to 1 in 10 people</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleepiness;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach ache;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being sick (vomiting);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gas (flatulence);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling bloated;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heartburn or acid reflux;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal blood test results (increased levels of certain liver enzymes).</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If any of the side effects get serious, or if you notice any side effects not mentioned in this leaflet, please tell your doctor or pharmacist. You can also report side effects directly via national reporting system listed in 6.&nbsp; By reporting side effects you can help provide more information on the safety of the medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on blister and the carton after EXP. The expiry date refers to the last day of that month.</p><p>Do not store above 30&deg;C.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is eluxadoline. Each tablet contains 100 mg of eluxadoline.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>Core tablet: silicified microcrystalline cellulose (E460); colloidal anhydrous silica (E551); crospovidone, type B (E1202); mannitol (E421) and magnesium stearate (E572).</p><p>Film-coating: polyvinyl alcohol (E1203); titanium dioxide (E171); macrogol 3350 (E1521); talc (E553b); iron oxide yellow (E172) and iron oxide red (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The film-coated tablets are modified capsule-shaped, pink-orange to peach and debossed with
‘FX100’ on one side.
The tablets are packed in PCTFE/PVC/Al-blisters. Viberzi is available in packs containing 28 coated tablets .


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer</strong></p><p>Patheon Pharmaceuticals Inc.</p><p>2110 E Galbraith Rd. Cincinnati, Ohio 45237</p><p>United States</p><p>&nbsp;</p><p><strong>Marketing Authorisation Holder and </strong></p><p>Allergan Pharmaceuticals International Limited Clonshaugh Industrial Estate</p><p>Coolock</p><p>Dublin 17 Ireland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was revised in May 2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>فايبرزي هو دواء يحتوي على المادة الفعالة إلوكسادولين ويُستخدم لعلاج متلازمة القولون العصبي &nbsp;المصحوبة بإسهال&nbsp; &nbsp;لدى البالغين</p><p>&nbsp;</p><p>:متلازمة القولون العصبي هي أحد اضطرابات الأمعاء الشائعة وتتضمن أعراض متلازمة القولون العصبي المصحوبة بإسهال الآتي</p><p>&nbsp; &nbsp; &nbsp;ألم في المعدة؛</p><p>&nbsp; اضطراب في المعدة؛</p><p>&nbsp; &nbsp; إسهال؛</p><p>&nbsp; &nbsp; &nbsp;حركات مفاجئة في الامعاء</p><p>&nbsp;</p><p>يعمل فايبرزي على سطح أمعائك لاستعادة الوظيفة الطبيعية للأمعاء وإيقاف الشعور بالألم والاضطراب في المرضى المصابين بمتلازمة القولون العصبي المصحوبة بإسهال</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p><strong>:لا تتناول فايبرزي في الحالات التالية</strong></p><p>&nbsp; &nbsp; إذا كان لديك حساسية لمادة الإلوكسادولين أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6)؛</p><p>&nbsp; &nbsp; إذا كنت مصاباً أو أصبت مسبقاً بالتهاب في البنكرياس؛</p><p>&nbsp; &nbsp; إذا لم يكن لديك مرارة منذ الولادة أو أزيلت مرارتك جراحياً؛</p><p>&nbsp; &nbsp;إذا كنت تعاني أو عانيت من مشكلات تعاطي المشروبات الكحولية أو إدمانها أو الإفراط في تناولها؛</p><p>&nbsp; &nbsp; &nbsp;إذا كنت مصاباً أو أصبت مسبقاً بانسداد في المرارة أو القنوات الصفراوية أو البنكرياس؛</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً أو أصبت مسبقاً بمرض أو اختلال في وظيفة عاصرة أودي (عضلة صغيرة مستديرة في الجزء العلوي من البطن تتحكم في تدفق العصارة الصفراوية وسوائل البنكرياس إلى الجزء العلوي من الامعاء)؛</p><p>&nbsp; &nbsp; &nbsp;إذا كنت تعاني من مرض في الكبد مع قصور في وظيفة الكبد؛</p><p>&nbsp; &nbsp; &nbsp;إذا كنت قد أصبت بالإمساك لفترة من الوقت أو كان الإمساك هو العرض الرئيسي لمتلازمة القولون العصبي (ويعرف باسم القولون العصبي المصحوب بإمساك ؛</p><p>&nbsp; &nbsp; &nbsp;إذا كنت مصاباً أو قد أصبت مسبقاً بانسداد في أمعائك؛</p><p>&nbsp; &nbsp; &nbsp;إذا كنت تتناول أدوية تتسبب في زيادة مستوى تركيز الإلوكسادولين في الدم (وتُعرف باسم مثبطات المناعة&nbsp; &nbsp;مثل سيكلوسبورين</p><p>&nbsp;</p><p>تحدث إلى طبيبك أو الصيدلي إذا كنت غير متأكد من انطباق أي من الأعراض السابقة عليك</p><p>&nbsp;</p><p><strong>الاحتياطات والتحذيرات</strong></p><p>:توقف عن تناول فايبرزي واحصل على العناية الطبية على الفور في حال ظهور أي من الأعراض التالية عليك خلال فترة تناول هذا الدواء</p><p>&nbsp; &nbsp; &nbsp;ألم جديد أو ألم شديد في منطقة البطن، مصحوباً أو غير مصحوب بشعور بالغثيان وقيء؛</p><p>&nbsp; قد يبدأ الشعور بالألم بعد البدء في تناول فايبرزي بوقت قصير. قد تشعر بألم على الجانب الأيمن من بطنك أو الجزء العلوي من البطن، أسفل الضلوع مباشرة. قد تشعر بأن الألم ينتقل إلى ظهرك أو كتفك؛</p><p>&nbsp; &nbsp; &nbsp; &nbsp;هذه الأعراض غير شائعة وقد تشير إلى وجود مشكلات في البنكرياس أو القناة المرارية أو التهاب البنكرياس أو تقلصات في عاصرة أودي</p><p>&nbsp; &nbsp; &nbsp;قد تزداد خطورة الإصابة بمشكلات في البنكرياس أو القناة الصفراوية إذا كنت تفرط في تناول المشروبات الكحولية؛</p><p>&nbsp; &nbsp; &nbsp; عادة ما تنتهي تقلصات عاصرة أودي عندما تتوقف عن تناول فايبرزي</p><p>&nbsp; &nbsp; &nbsp;استمرار الإمساك لأكثر من 4 أيام</p><p>&nbsp;</p><p>:يُرجى إبلاغ الطبيب بالتالي</p><p>&nbsp; &nbsp; &nbsp;كمية الكحول التي تتناولها (عدد المشروبات الكحولية التي تتناولها يومياً)؛</p><p>&nbsp; &nbsp; &nbsp;في حال إصابتك بآثار جانبية مثل الدوار والنعاس</p><p>&nbsp;</p><p>توخى الحرص الشديد إذا كان عمرك 65 عاماً أو أكثر، حيث يزداد خطر الإصابة ببعض الآثار الجانبية المحددة (انظر قسم 4</p><p><strong>&nbsp;</strong></p><p><strong>الأطفال والمراهقين</strong></p><p>لا يجب إعطاء فايبرزي للأطفال والمراهقين دون 18 عاماً حيث لا تتوفر أي معلومات عن استخدامه في هذه المجموعة العمرية</p><p>&nbsp;</p><p><strong>التفاعلات مع الأدوية الأخرى</strong></p><p>أخبر الطبيب أو الصيدلي إذا كنت تتناول أو قد تناولت مؤخراً أو ربما تتناول أي أدوية أخرى</p><p>&nbsp;</p><p>تجنب الاستخدام المتكرر لدواء لوبيراميد (دواء يستخدم لعلاج الإسهال) إذا كنت تتناول فايبرزي فربما يؤدي ذلك إلى زيادة خطر الإصابة بالإمساك. تجنب تناول فايبرزي مع أي أدوية أخرى قد تسبب الإمساك مثل المواد الافيونية (مثل الفينتانيل [الذي يستخدم لعلاج الألم] أو مضادات الكولين (مثل الأتروبين [الذي يستخدم لعلاج الاضطرابات القلبية من بين استخدامات أخرى</p><p>&nbsp;</p><p>:قد تؤدي بعض الأدوية إلى زيادة مستوى فايبرزي في الدم. وتشمل هذه الأدوية</p><p>&nbsp; &nbsp; &nbsp;سيكلوسبورين (دواء مثبط للمناعة يستخدم لتقليل الالتهاب)؛</p><p>&nbsp; &nbsp;جمفبروزيل&nbsp;(يُستخدم لخفض مستويات الدهون)؛</p><p>&nbsp; &nbsp; &nbsp;أتازانافير، لوبينافير، ساكوينافر، تيبرانافير (مضادات الفيروسات القهقرية المستخدمة لعلاج فيروس نقص المناعة البشرية)؛</p><p>&nbsp; &nbsp; ريفامبيسين (مضاد حيوي يستخدم لعلاج العدوى).</p><p>&nbsp;</p><p>:لا تتناول فايبرزي مع أي من الأدوية التالية</p><p>:قد يؤدي فايبرزي إلى زيادة مستوى بعض الأدوية في الدم. وتشمل هذه الأدوية</p><p>&nbsp; &nbsp; &nbsp;رسيوفاستاتين (ستاتين يُستخدم لعلاج ارتفاع مستوى الكوليسترول وللوقاية من الأمراض القلبية الوعائية)؛</p><p>&nbsp; &nbsp; &nbsp;فالسارتان وأولميسارتان (يُستخدم لعلاج ارتفاع ضغط الدم)؛</p><p>&nbsp; &nbsp; إريثرومايسين (يُستخدم لعلاج العدوى)؛</p><p>&nbsp; &nbsp;ميدازولام (دواء يُستخدم للتهدئة والتسكين على سبيل المثال عندما تخضع لعمليات التنظير)؛</p><p>&nbsp; &nbsp;نيفيديبين (يُستخدم لعلاج ضغط الدم المرتفع)؛</p><p>&nbsp; &nbsp; &nbsp;ألفينتانيل، فينتانيل (مادة أفيونية تُستخدم لعلاج الألم)؛</p><p>&nbsp; ثنائي هيدروإرغوتامين، إرغوتامين (يُستخدم لعلاج الصداع النصفي)؛</p><p>&nbsp; &nbsp; &nbsp;بيموزيد (يُستخدم لعلاج الاضطرابات العقلية)؛</p><p>&nbsp; كينيدين (يُستخدم لعلاج أمراض القلب)؛ &nbsp;</p><p>&nbsp; &nbsp; &nbsp;سيروليموس، تاكروليموس (دواء مثبط للمناعة يُستخدم للتحكم في الاستجابة المناعية للجسم).</p><p>إذا انطبقت عليك أي من الحالات السابقة، أخبر طبيبك أو الصيدلي قبل تناول فايبرزي. استشر طبيبك أو الصيدلي إذا لم تكن متأكداً</p><p>&nbsp;</p><p><strong>الحمل والرضاعة الطبيعية</strong></p><p>لا يجب تناول فايبرزي إذا كنتِ في فترة الحمل أو الرضاعة الطبيعية. إذا كنتِ حاملاً أو مرضعاً أو تعتقدين بأنكِ حامل أو أنكِ تخططين للحمل، فاطلبي النصيحة من الطبيب قبل تناول هذا الدواء</p><p>&nbsp;</p><p><strong>القيادة وتشغيل الآلات</strong></p><p>من غير المحتمل أن يؤثر فايبرزي في قدرتك على القيادة أو استخدام الأدوات أو الآلات. بالرغم من ذلك، قد تظهر عليك بعض الآثار الجانبية مثل الشعور بالنعاس أو الدوار أثناء تناول فايبرزي الذي قد يؤثر في قدرتك على القيادة أو تشغيل الآلات. تجنب القيادة أو استخدام الآلات خلال فترة العلاج بهذا الدواء حتى تتأكد من كيفيه تأثيره عليك</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول هذا الدواء دائماً حسب وصف الطبيب. استشر طبيبك إذا لم تكن متأكداً</p><p>&nbsp;</p><p>الجرعة الموصى بها هي قرص واحد 100 ملجم مرتين يومياً</p><p>يجب تناول هذه الأقراص عن طريق الفم مع الطعام في الصباح وفي المساء</p><p>&nbsp;</p><p><strong>في حال تناول جرعة زائدة من فايبرزي</strong></p><p>في حال تناول جرعة زائدة من فايبرزي أخبر طبيبك أو اطلب المساعدة الطبية العاجلة</p><p>&nbsp;</p><p><strong>في حال نسيان تناول فايبرزي</strong></p><p>لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية. تناول الجرعة التالية في موعدها المحدد وواصل تناول الجرعات في أوقاتها المعتادة</p><p>&nbsp;</p><p><strong>في حال التوقف عن تناول فايبرزي</strong></p><p>لا تتوقف عن تناول فايبرزي دون التحدث مع طبيبك أولاً فقد تزداد حالة الأعراض سوءاً</p><p>&nbsp;</p><p>إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، سل طبيبك أو الصيدلي</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>شأنه شأن جميع الأدوية، قد يسبب هذا الدواء بعض الآثار الجانبية، ولكن ليس بالضرورة أن تظهر على جميع الأشخاص</p><p><strong>&nbsp;</strong></p><p><strong>قد تكون بعض الآثار الجانبية خطيرة</strong></p><p>توقف عن تناول فايبرزي واطلب الرعاية الطبية على الفور إذا شعرت ألم جديد أو ألم شديد في منطقة البطن، مصحوباً أو غير مصحوب بشعور بالغثيان وقيء، خلال فترة تناول فايبرزي. تحدث هذه الأعراض بشكل غير شائع (قد تؤثر في شخص واحد من كل 100 شخص) وقد تشير إلى وجود مشكلات في البنكرياس أو القناة المرارية (مثل التهاب البنكرياس أو تقلصات في عاصرة أودي</p><p>&nbsp;</p><p><strong>:تشمل الآثار الجانبية الأخرى</strong></p><p>آثار جانبية شائعة: قد تؤثر في شخص واحد من كل 10 أشخاص</p><p>&nbsp; &nbsp; &nbsp;الدوار؛</p><p>&nbsp; &nbsp; &nbsp;الشعور بالنعاس؛</p><p>&nbsp; &nbsp; الإمساك؛</p><p>&nbsp; &nbsp; &nbsp;الشعور بالإعياء (الغثيان)؛</p><p>&nbsp; &nbsp; &nbsp;ألم في المعدة؛</p><p>&nbsp; &nbsp; &nbsp;الإعياء (القيء)؛</p><p>الغازات (الانتفاخ)؛</p><p>الشعور بالانتفاخ؛</p><p>حرقة المعدة أو ارتجاع المريء؛</p><p>الطفح الجلدي؛</p><p>&nbsp; &nbsp; تغيرات في نتائج اختبارات الدم (زيادة مستويات بعض إنزيمات الكبد</p><p>&nbsp;</p><p><strong>الإبلاغ عن حدوث الآثار الجانبية</strong></p><p>إذا تطور أي من هذه الآثار الجانبية لدرجة خطيرة، أو إذا لاحظت حدوث أي آثار&nbsp; جانبية غير واردة بهذه النشرة، أخبر الطبيب أو الصيدلي. يمكنك أيضاً الإبلاغ عن الآثار الجانبية مباشرة من خلال نظام الإبلاغ الوطني المذكور في القسم 6. إن الإبلاغ عن الآثار الجانبية من شأنه المساعدة من خلال توفير المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ هذا الدواء بعيداً عن متناول الأطفال ومرمى نظرهم</p><p>EXPلا يستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية الموضح على الشريط والعلبة بعد كلمة&nbsp;</p><p>ويشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر</p><p>يُحفظ في درجة حرارة لا تزيد عن 30 درجة مئوية</p><p>لا ينبغي التخلص من أي أدوية عن طريق مياه الصرف أو النفايات المنزلية. سل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد تستعملها. تساعد هذه التدابير في حماية البيئة</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي إلوكسادولين. يحتوي كل قرص على 100 ملجم إلوكسادولين</p><p>&nbsp; &nbsp;: المكونات الأخرى هي</p><p>القرص من الداخل: سيلولوز دقيق البلورات مع سيليكون، سيليكا غروانية لا مائية ؛ كروسبوفيدون، نوع ب&nbsp; مانيتول وستيارات ماغنيسيوم&nbsp;</p><p>الطبقة الخارجية للقرص: كحول بولي فينيل ؛ ثاني أكسيد تيتانيوم ؛ ماكروغول ؛ تلك ؛ أكسيد حديد أصفر ، أكسيد حديد أحمر&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            تأتي الأقراص المغلفة على شكل كبسولات معدلة باللون الوردي-البرتقالي المائل إلى لون ثمر الخوخ ومحفور عليها ‘FX100’ على أحد الجانبين.
الأقراص معبأة في شرائط مغلفة بمادة   PCTFE/PVC/Al . يتوفر دواء فايبرزي في عبوات تحتوي كل منها على 28 قرص مغلف

        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>الشركة المصنعة</strong></p><p>شركة باثيون للصناعات الدوائية</p><p>2110 طريق إي جالبريث، سينسيناتي، أوهايو 45237</p><p>الولايات المتحدة الأمريكية</p><p>&nbsp;</p><p><strong>الشركة المالكة لحق التسويق </strong></p><p>شركة أليرجان العالمية للصناعات الدوائية المحدودة</p><p>منطقة كلونشو الصناعية</p><p>كولوك</p><p>دبلن 17 أيرلندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم مراجعة هذه النشرة في مايو 2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Viberzi 75 mg film-coated tablets. 
Viberzi 100 mg film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Viberzi 75 mg film-coated tablets
Each film-coated tablet contains 75 mg of eluxadoline.

Viberzi 100 mg film-coated tablets
Each film-coated tablet contains 100 mg of eluxadoline. For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Viberzi 75 mg film-coated tablets
Modified capsule-shaped, pale yellow to light-tan film-coated tablet of approximately 7 mm x 17 mm, debossed with “FX75” on one side.

Viberzi 100 mg film-coated tablets
Modified capsule-shaped, pink-orange to peach film-coated tablet of approximately 8 mm x 19 mm, debossed with “FX100” on one side.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Viberzi </u>is indicated in adults for the treatment of irritable bowel syndrome with diarrhoea (IBS-D).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The recommended dose is 200 mg daily (one 100 mg tablet, twice daily).</p><p>For patients who are unable to tolerate the 200 mg daily dose (one 100 mg tablet, twice daily), the dose can be lowered to 150 mg daily (one 75 mg tablet twice daily).</p><p>&nbsp;</p><p><em>E</em><em>ld</em><em>e</em><em>r</em><em>ly</em></p><p>In principle, general dose recommendations also apply to patients aged 65 years and above.</p><p>However, given the potential for increased sensitivity to experience undesirable effects, it may be considered to initiate eluxadoline treatment in a dosage of 150 mg daily (one 75 mg tablet twice daily). If this dosage is well tolerated, but not sufficiently effective, dosage may subsequently be increased to 200 mg daily (one 100 mg tablet twice daily). See section 4.4.</p><p>&nbsp;</p><p><em>P</em><em>atients with renal impairment</em></p><p>The safety and pharmacokinetics of eluxadoline in patients with renal impairment have not yet been established. With the renal route being a minor route of elimination for eluxadoline, no dose adjustment based on renal function may be necessary (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em>P</em><em>aediatric population</em></p><p>The safety and efficacy of eluxadoline in children aged 0 to18 years have not yet been established. No data are available.</p><p>Benefits and risks of the treatment should be periodically assessed in the context of patient symptoms severity.</p><p>&nbsp;</p><p><u>Method of administration</u> For oral use.</p><p>The tablets should be taken with food in the morning and in the evening (see section 5.2).</p><p>Patients should be instructed if they miss a dose (delay of 4 hours) to take the next dose at the regular time and not to take 2 doses at the same time to make up for a missed dose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to eluxadoline or to any of the excipients listed in section 6.1.
•	Alcoholism, alcohol abuse, alcohol addiction or chronic or acute excessive alcohol use. These patients are at increased risk for acute pancreatitis (see section 4.4).
•	Known or suspected biliary duct obstruction or sphincter of Oddi disease or dysfunction. These patients are at increased risk for sphincter of Oddi spasm (see section 4.4).
•	Patients without a gallbladder ( e.g. due to cholecystectomy or agenesis). These patients are also at increased risk for sphincter of Oddi spasm (see section 4.4).
•	Patients on treatment with potent inhibitors of OATP1B1 (e.g. cyclosporine)
•	A history of pancreatitis; or known or suspected structural diseases of the pancreas, including pancreatic duct obstruction. These patients are at increased risk for acute pancreatitis (see section 4.4).
•	Hepatic impairment (Child-Pugh Class A-C). These patients are at risk for significantly increased plasma concentrations of eluxadoline (see sections 4.4 and 5.2).
•	A history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction. These patients may be at risk for severe complications of bowel obstruction.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Sphincter of Oddi Spasm</u></p><p>Given the mu opioid receptor agonism of eluxadoline, there is a potential for increased risk of sphincter of Oddi spasm, resulting in pancreatitis or hepatic enzyme elevation associated with acute abdominal pain (eg, biliary-type pain) in patients taking eluxadoline, especially in patients without a gallbladder (see sections 4.3 and 4.8). Patients with known or suspected sphincter of Oddi disease or dysfunction and/or biliary tract or pancreatic disease, including a history of pancreatitis, and those who have had a cholecystectomy or are missing a gallbladder due to other reasons must not receive this medicinal product (see section 4.3).</p><p>Patients should be instructed to stop the treatment and seek medical attention if they experience symptoms suggestive of sphincter of Oddi spasm such as acute worsening of abdominal pain (e.g. acute epigastric or biliary [i.e., right upper quadrant] pain) that may radiate to the back or shoulder, with or without nausea and vomiting. Eluxadoline should not be restarted in patients who developed biliary duct obstruction or sphincter of Oddi spasm while taking eluxadoline (see section 4.3).</p><p>&nbsp;</p><p><u>Pancreatitis</u></p><p>There is a potential for increased risk of pancreatitis, not associated with sphincter of Oddi spasm, when taking eluxadoline (see section 4.8). All patients should be instructed to avoid chronic or acute excessive alcohol use while taking eluxadoline. Patients should be monitored for new or worsening</p><p>abdominal pain, that may radiate to the back or shoulder , with or without nausea and vomiting. Patients should be instructed to stop the medicinal product and seek medical attention if these symptoms develop while taking eluxadoline (see section 4.8).</p><p>&nbsp;</p><p><u>Constipation</u></p><p>There is a potential for increased risk of constipation when taking eluxadoline (see section 4.8). If patients develop severe constipation for a duration of more than 4 days, they should be instructed to stop the treatment and seek medical attention.</p><p>Risk of constipation with eluxadoline in patients with other IBS sub-types is unknown, but may be increased. Caution should be exercised when administering eluxadoline in IBS patients whose bowel habits vary over time.</p><p>&nbsp;</p><p><u>Somnolence and sedation</u></p><p>There is a potential for increased risk of somnolence and sedation when taking eluxadoline (see section 4.8) in patients who may experience increased plasma levels, such as in patients with a genetic predisposition for poor function of OATP1B1 transporter. As patient&rsquo;s genetic disposition may be unknown, it is recommended that patients be monitored for impaired mental or physical abilities needed to perform potentially hazardous activities such as driving a car or using machines (see sections 4.7. and&nbsp; 4.8).</p><p>&nbsp;</p><p><u>Drug dependence and potential for abuse</u></p><p>Based on the physical-chemical and biopharmaceutical properties (very low oral bioavailability), eluxadoline is expected to have minimal abuse or dependence liability.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>E</em><em>l</em><em>derly</em></p><p>Overall, there was an increased frequency of adverse events reported for patients aged 65 years or greater in the clinical studies. However, patients 65 years of age and older, treated with the 75 mg dose twice daily experienced a reduced rate of serious adverse events as well as adverse events leading to discontinuation compared to patients treated with 100 mg dose twice daily (see section 4.8).&nbsp; Therefore, the 75 mg dose twice daily can be considered for this population, but its benefit risk ratio should be periodically assessed in the context of their symptoms severity (see section 4.2).</p><p>&nbsp;</p><p><em>P</em><em>aediatric population</em></p><p>Eluxadoline should not be used in children and adolescents as it has not been studied in this population (see section 4.2).</p><p>&nbsp;</p><p><em>R</em><em>enal impairment</em></p><p>No data on the pharmacokinetics of eluxadoline in patients with renal impairment are available (see section 5.2). Due to minimal absorption and the negligible role for renal elimination, an influence of renal impairment on the plasma levels of eluxadoline is not expected.</p><p>&nbsp;</p><p><em>H</em><em>epatic impairment</em></p><p>Eluxadoline must not be used in patients with a history of or known or suspected hepatic impairment (Child-Pugh Class A-C) (see section 4.3).</p><p>&nbsp;</p><p><em>E</em><em>ff</em><em>e</em><em>ct of OATP1B1 transporter function variability on plasma levels</em></p><p>The plasma levels in patients with a genetic predisposition for poor function of OATP1B1 transporter are increased, and in these patients a higher rate of adverse events, especially with regard to gastrointestinal events, as well as CNS effects might be expected (see section 5.2).</p><p>&nbsp;</p><p><em>B</em><em>il</em><em>e acid malabsorption</em></p><p>A relevant proportion of patients diagnosed with IBS-D may be affected by bile-acid malabsorption as a potential reason for IBS-D symptoms. The safety and efficacy of eluxadoline in this subgroup of IBS-D patients has not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Medicinal products that cause constipation</u></p><p>Although no direct drug-drug interactions have been demonstrated, chronic use of loperamide with eluxadoline should be avoided as this may increase the risk of constipation. The use of eluxadoline with other medicinal products that may cause constipation (for example anticholinergics, opioids etc) should also be avoided.</p><p>&nbsp;</p><p><u>OATP1B1 inhibitors</u></p><p>Co-administration of OATP1B1 inhibitors (cyclosporine, gemfibrozil, antiretrovirals [atazanavir, lopinavir, ritonavir, saquinavir, tipranavir], rifampin) with eluxadoline may increase exposure to eluxadoline (see section 5.2). Eluxadoline should not be administered concomitantly with such medicinal products (see section 4.3).</p><p>&nbsp;</p><p><u>OATP1B1 substrates</u></p><p>Eluxadoline increases the exposure of the co-administered OATP1B1 substrate; rosuvastatin (see section 5.2) by up to 40% of the total exposure which is usually not considered to be clinically relevant. The effect on other statins which are more sensitive OATP1B1 substrates (e.g. simvastatin and atorvastatin), however, may be more pronounced. Caution should therefore be exercised in patients receiving such medicinal products especially with high doses.</p><p>Other substrates potentially affected include e.g. sartans (valasartan, olmesaran).</p><p>&nbsp;</p><p><u>CYP3A substrates</u></p><p>Eluxadoline may increase the exposure of co-administered medicinal products metabolised by Cytrochrome CYP3A4. Caution should be exercised when administering such products (e.g. midazolam, erythromycin, nifedipine), especially for those with a narrow therapeutic index (e.g. alfentanil, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus). The concentration of these co-administered medicinal products with a narrow therapeutic index or their other pharmacodynamic markers should be monitored when concomitant use with eluxadoline is initiated or discontinued.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There is limited amount of data from the use of eluxadoline in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of<u> </u>Viberzi during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is unknown whether eluxadoline is excreted in human milk. Available pharmacodynamic/toxicological data in animals have shown excretion of eluxadoline in milk (for details see section 5.3). A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Viberzi therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No human data on the effect of eluxadoline on fertility are available. In rats, there was no effect on mating, fertility and fecundity indices (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Eluxadoline has a minor influence on the ability to drive and use machines.</p><p>Due to events of somnolence and sedation observed in clinical studies, caution should be exercised (see sections 4.4 and 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most common adverse reactions (incidence of &gt;5%) reported were constipation (7% and 8% of patients receiving 75 mg and 100 mg respectively), nausea (8% and 7% of patients receiving 75 mg and 100 mg respectively) and abdominal pain (6% and 7% of patients receiving 75 mg and 100 mg respectively). Serious adverse reactions of pancreatitis (0.2% and 0.3% of patients receiving 75 mg and 100 mg respectively) and sphincter of Oddi spasm (0.2% of patients receiving 75 mg and 0.8% of patients receiving 100 mg) may also occur.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions are presented according to the MedDRA System Organ Classification and frequency convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000) and not known (cannot be estimated from the available data).</p><table border="1" cellspacing="1" cellpadding="1" style="height:400px; width:800px"><tbody><tr><td style="width:212px"><em>System organ class</em></td><td style="width:183px"><em>Common</em></td><td style="width:404px">Uncommon</td></tr><tr><td style="width:212px"><em>Nervous system disorders</em></td><td style="width:183px"><p>Dizziness</p><p>Somnolence1</p></td><td style="width:404px">&nbsp;</td></tr><tr><td style="width:212px"><em>Gastrointestinal disorders</em></td><td style="width:183px"><p>Constipation</p><p>Nausea</p><p>Abdominal pain2</p><p>Vomiting</p><p>Flatulence</p><p>&nbsp;Abdominal distention&nbsp; &nbsp; &nbsp;Gastroesophageal reflux</p><p>disease 4</p></td><td style="width:404px"><p>Sphincter of Oddi spasm3</p><p>Pancreatitis</p></td></tr><tr><td style="width:212px"><em>Skin and subcutaneous tissue disorders</em></td><td style="width:183px">Rash 5</td><td style="width:404px">&nbsp;</td></tr><tr><td style="width:212px"><em>Investigations</em></td><td style="width:183px"><p>Increased ALT</p><p>Increased AST</p></td><td style="width:404px">&nbsp;</td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>1&ldquo;Somnolence&rdquo; term includes: somnolence and sedation.</p><p>2&ldquo;Abdominal pain&quot; term includes: abdominal pain, abdominal pain lower, and abdominal pain upper.</p><p>3&nbsp;&nbsp;&nbsp; &ldquo;Sphincter of Oddi spasm&rdquo; term includes: manifestation as pancreatitis (terms include alcoholic pancreatitis, pancreatitis, and pancreatitis acute) and hepatic enzyme elevations with abdominal pain</p><p>(terms include abdominal pain, abdominal pain upper, dyspepsia, and sphincter of Oddi dysfunction).</p><p>4&nbsp;&nbsp; &ldquo;Gastrooesophageal reflux disease&rdquo; term includes gastrooesophageal reflux disease, dyspepsia and gastritis.</p><p>5&nbsp;&nbsp; &ldquo;Rash&quot; term includes: dermatitis, dermatitis allergic, rash, rash generalized, rash macula-papular, rash papular, rash pruritic, urticaria, and idiopathic urticarial.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em>C</em><em>onstipation</em></p><p>Approximately 50% of constipation events occurred within the first 2 weeks of treatment.</p><p>Rates of severe constipation were less than 1% in patients receiving 75 mg and 100 mg eluxadoline and there were no serious complications of constipation related to eluxadoline use in pivotal studies. 1% of patients receiving 75 mg and 2% of patients receiving 100 mg discontinued treatment or temporarily suspended dosing secondary to constipation, respectively, compared to &lt;1% of patients treated with placebo. Patients should be instructed to stop the medicinal product and seek medical attention if they develop severe constipation for more than 4 days (see section 4.4).</p><p>&nbsp;</p><p><em>Sphincter of Oddi spasm</em></p><p>In clinical studies, events of sphincter of Oddi spasm manifested as elevated hepatic enzymes associated with abdominal pain in 8 patients, pancreatitis in 1 patient and abdominal pain with lipase elevation less than 3 times the upper limit of normal in 1 patient. 80% (8/10) of sphincter of Oddi spasm events presented within the first week of treatment. All events resolved upon discontinuation of Viberzi, with symptoms typically improved by the following day. All events of sphincter of Oddi spasm occurred in patients without a gallbladder. Therefore, eluxadoline is contraindicated in this population as well as in those with previous biliary tract problems (see sections 4.2, 4.3 and 4.4). The occurrence of such events in patients with an intact biliary tract cannot be excluded.</p><p>&nbsp;</p><p><em>P</em><em>ancreatitis</em></p><p>Additional cases of pancreatitis not associated with sphincter of Oddi spasm were reported in clinical studies. Of the 5 cases reported, 3 were associated with excessive alcohol intake, 1 was associated with biliary sludge, and in one case the patient discontinued eluxadoline 2 weeks prior to the onset of symptoms.</p><p>All pancreatic events, whether or not associated with sphincter of Oddi spasm, were retrospectively evaluated as mild, indicating an absence of organ failure and local or systemic complications. All pancreatic events resolved with lipase normalization upon discontinuation of eluxadoline, with 80% (4/5) resolving within 1 week of treatment discontinuation (see section 4.4).</p><p>&nbsp;</p><p><em>E</em><em>l</em><em>derly</em></p><p>Of 1,795 IBS-D patients who were enrolled in clinical studies of eluxadoline and assigned to 75 mg or 100 mg twice daily, 139 (7.7%) were at least 65 years of age, while 15 (0.8%) were at least 75 years old.</p><p>There was an overall increased frequency of adverse events in the older population compared to patients &lt;65 years which was comparable across all treatment groups, including placebo.</p><p>The frequency of serious adverse events, gastrointestinal events, and events leading to discontinuation tended to be lower for the 75 mg dose compared to the 100 mg dose. Therefore, in this population, the 75 mg dose twice daily can be used. (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p><strong>The national pharmacovigilance center and drug safety center</strong> (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: &nbsp;+966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at &nbsp;+966-11-20382222, Exts: 2353-2356-2317-2354-2334-2340</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 8002490000</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: <u>npc.drug@sfda.gov.sa</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: <u>www.sfda.gov.sa/npc</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>Single supratherapeutic oral doses of eluxadoline up to 1,000 mg and single intranasal doses up to 200 mg were associated with a higher incidence of adverse events than a 100 mg single dose, especially gastrointestinal and central nervous system events. An overdose of eluxadoline may result in symptoms resulting from an exaggeration of the known pharmacodynamic effects of the medicinal product.</p><p>&nbsp;</p><p><u>Management</u></p><p>In the event of acute overdose, the patient should be carefully observed and given standard supportive treatment as required. Gastric lavage or charcoal administration should be considered. Given eluxadoline&rsquo;s action at opioid receptors, administration of a narcotic mu opioid antagonist, such as naloxone, should be considered. Considering the short half-life of naloxone, repeated administration may be necessary. In the event of naloxone administration, subjects should be monitored closely for the return of overdose symptoms, which may indicate need for repeated naloxone injection.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: ANTIPROPULSIVES , ATC code: A07D</p><p><u>Mechanism of action</u></p><p>Eluxadoline is a locally acting, mixed mu opioid receptor (&mu;OR) agonist and delta opioid receptor (&delta;OR) antagonist. Eluxadoline is also an agonist at the kappa opioid receptor (&kappa;OR). The binding affinities (Ki) of eluxadoline for human &mu;OR and &delta;OR are 1.8 nM and 430 nM, respectively. The binding affinity (Ki) of eluxadoline for human &kappa;OR has not been determined; however, the Ki for guinea pig cerebellum &kappa;OR is 55 nM. In animals, eluxadoline interacts with opioid receptors in the gut. Eluxadoline has demonstrated efficacy in normalizing GI transit and defecation in several models of stress induced or post GI inflammation-altered GI function in animals. Eluxadoline has very low oral bioavailability and exerts no detectable central nervous system (CNS)-mediated effects when administered orally to animals at effective doses. Eluxadoline also reverses hyperalgesic responses in an animal model of acute colitis-induced visceral pain.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Since bioavailability is limited, the pharmacodynamic activity of eluxadoline is based predominantly on local action within the GI tract. Supporting the lack of systemic pharmacodynamic effects are results from an oral abuse liability study in recreational opioid users that showed oral doses up to 1,000 mg did not produce significant pupillary constriction or significant drug liking. An abuse liability study with 100 mg and 200 mg intranasal doses of eluxadoline resulted in higher systemic concentrations of eluxadoline that produced changes in pupil diameter but were associated with drug disliking. In patients with IBS-D, no signal for central nervous system-mediated adverse events was identified. Taken together these results suggest that when using the medicinal product as directed at therapeutic doses patients will not experience significant central nervous system effects or adverse events consistent with a drug of abuse.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>The efficacy and safety of eluxadoline in IBS-D patients was established in two randomized, multi- center, multi-national, double-blind, placebo-controlled studies (Studies 1 &amp; 2). A total of</p><p>1,282 patients in Study 1 (IBS-3001) and 1,146 patients in Study 2 (IBS-3002) were enrolled and received treatment with Viberzi 75 mg, Viberzi 100 mg or placebo twice daily. Overall, patients had a mean age of 45 years (range 18-80 years with 10% at least 65 years of age or older), 66% female, 86% white, 12% black, and 27% Hispanic.</p><p>All patients met Rome III criteria for IBS and were required to meet the following criteria:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an average of worst abdominal pain (WAP) scores in the past 24 hours of &gt;3.0 on a 0 to 10 scale over the week prior to randomization.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an average daily stool consistency score (BSS) of &ge;5.5 and at least 5 days with a BSS score &ge;5</p><p>on a 1 to 7 scale over the week prior to randomization.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an average global symptom score &gt;2.0 on a 0-4 scale (0 corresponds to no symptoms, 1 corresponds to mild symptoms, 2 corresponds to moderate symptoms, 3 corresponds to severe symptoms and 4 corresponds to very severe symptoms) over the week prior to randomization</p><p>&nbsp;</p><p>The study designs were identical through the first 26 weeks. Study1 (IBS-3001) continued double-blinded for an additional 26 weeks for long-term safety (total of 52 weeks of treatment), followed by a 2-week follow-up. Study 2 (IBS-3002) included a 4-week single-blinded, placebo-withdrawal period upon completion of the 26-week treatment period.</p><p>&nbsp;</p><p>Efficacy of eluxadoline was assessed using an overall responder analyses as defined by the simultaneous improvement in the daily WAP score by &ge;30% as compared to the baseline weekly average AND a reduction in the BSS to &lt;5 on at least 50% of the days within a time interval. Improvements in global symptoms of IBS were assessed based on an adequate relief response endpoint defined as achieving adequate relief of IBS symptoms on at least 50% of weeks and on a global symptom response endpoint defined by a daily rating of global symptoms of none or mild on at least 50% of days. Results for endpoints were based on electronic daily diary entries by patients.</p><p>The efficacy results for &ge;50% of responder days (primary composite endpoint) over 6 months are</p><p>shown in Table 2. In both studies, the proportion of patients who were composite responders to 100 mg twice daily was statistically significantly higher than placebo. The proportion of</p><p>&nbsp;</p><p>patients who were adequate relief responders was statistically significantly higher than placebo for Viberzi 100 mg twice daily over 6 month interval in both studies. The proportion of patients who were global symptom responders was statistically significantly higher than placebo for Viberzi</p><p>100 mg twice daily over 6 month interval in Study 2 and numerically higher than placebo in Study 1.</p><p>There were no efficacy differences according to gender.</p><p>Table 2: Efficacy Results in Randomized Clinical Studies</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><table border="1" cellspacing="1" cellpadding="1" style="width:691px"><tbody><tr><td rowspan="2" colspan="1" style="width:136px">&nbsp;</td><td rowspan="1" colspan="3" style="width:258px"><strong>Study 1 (IBS 3001)</strong></td><td rowspan="1" colspan="3" style="width:304px"><strong>Study 2 (IBS 3002)</strong></td></tr><tr><td style="width:75px"><strong>Viberzi</strong> <strong>100 mg n=426</strong></td><td style="width:96px"><strong>Viberzi</strong> <strong>75 mg n=427</strong></td><td style="width:99px"><strong>Placebo n=427</strong></td><td style="width:95px"><p><strong>Viberzi</strong> <strong>100 mg n=382</strong></p></td><td style="width:93px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Viberzi</strong> <strong>75 mg n=381</strong></p></td></tr></tbody></table></td><td style="width:119px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Pla</strong><strong>cebo n=382</strong></p></td></tr></tbody></table></td></tr><tr><td style="width:136px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>C</strong><strong>o</strong><strong>m</strong><strong>po</strong><strong>s</strong><strong>i</strong><strong>te Response</strong></p></td></tr><tr><td style="vertical-align:top"><p>Responder rates</p></td></tr><tr><td style="vertical-align:top"><p>P values</p></td></tr></tbody></table></td><td style="width:75px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>29%</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>&lt;0.001</p></td><td>&nbsp;</td></tr></tbody></table></td><td style="width:96px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>23%</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>0.112</p></td><td>&nbsp;</td></tr></tbody></table></td><td style="width:99px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>19%</p></td></tr></tbody></table></td><td style="width:95px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>33%</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>&lt;0.001</p></td><td>&nbsp;</td></tr></tbody></table></td><td style="width:93px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>30%</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>0.001</p></td><td>&nbsp;</td></tr></tbody></table></td><td style="width:119px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>20%</p></td></tr></tbody></table></td></tr><tr><td style="width:136px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>A</strong><strong>bdo</strong><strong>mi</strong><strong>n</strong><strong>a</strong><strong>l Pain Response</strong></p></td></tr><tr><td style="vertical-align:top"><p>Responder rates</p></td></tr><tr><td style="vertical-align:top"><p>P values</p></td></tr></tbody></table></td><td style="width:75px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>47%</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>0.355</p></td><td>&nbsp;</td></tr></tbody></table></td><td style="width:96px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>45%</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>0.852</p></td><td>&nbsp;</td></tr></tbody></table></td><td style="width:99px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>43%</p></td></tr></tbody></table></td><td style="width:95px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>50%</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>0.148</p></td><td>&nbsp;</td></tr></tbody></table></td><td style="width:93px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>48%</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>0.448</p></td><td>&nbsp;</td></tr></tbody></table></td><td style="width:119px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>45%</p></td></tr></tbody></table></td></tr><tr><td style="width:136px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>B</strong><strong>S</strong><strong>S &lt;5 Response</strong></p></td></tr><tr><td style="vertical-align:top"><p>Responder rates</p></td></tr><tr><td style="vertical-align:top"><p>P values</p></td></tr></tbody></table></td><td style="width:75px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>34%</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>0.001</p></td><td>&nbsp;</td></tr></tbody></table></td><td style="width:96px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>28%</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>0.186</p></td><td>&nbsp;</td></tr></tbody></table></td><td style="width:99px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>24%</p></td></tr></tbody></table></td><td style="width:95px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>40%</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>&lt;0.001</p></td><td>&nbsp;</td></tr></tbody></table></td><td style="width:93px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>34%</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>&lt;0.001</p></td><td>&nbsp;</td></tr></tbody></table></td><td style="width:119px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>24%</p></td></tr></tbody></table></td></tr><tr><td style="width:136px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>A</strong><strong>d</strong><strong>equate Relief Response</strong></p></td></tr><tr><td style="vertical-align:top"><p>Responder rates</p></td></tr><tr><td style="vertical-align:top"><p>P values</p></td></tr></tbody></table></td><td style="width:75px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>49.5%</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>0.005</p></td><td>&nbsp;</td></tr></tbody></table></td><td style="width:96px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>45.7%</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>0.097</p></td><td>&nbsp;</td></tr></tbody></table></td><td style="width:99px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>40.0%</p></td></tr></tbody></table></td><td style="width:95px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>53.7%</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>0.006</p></td><td>&nbsp;</td></tr></tbody></table></td><td style="width:93px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>52.8%</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>0.013</p></td><td>&nbsp;</td></tr></tbody></table></td><td style="width:119px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>43.7%</p></td></tr></tbody></table></td><td>&nbsp;</td></tr></tbody></table></td></tr><tr><td style="width:136px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>G</strong><strong>l</strong><strong>o</strong><strong>bal Symptom Response</strong></p></td></tr><tr><td style="vertical-align:top"><p>Responder rates</p></td></tr><tr><td style="vertical-align:top"><p>P values</p></td></tr></tbody></table></td><td style="width:75px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>34.7%</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>0.063</p></td><td>&nbsp;</td></tr></tbody></table></td><td style="width:96px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>35.1%</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>0.048</p></td><td>&nbsp;</td></tr></tbody></table></td><td style="width:99px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>28.8%</p></td></tr></tbody></table></td><td style="width:95px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>43.2%</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>0.012</p></td><td>&nbsp;</td></tr></tbody></table></td><td style="width:93px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>45.1%</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>0.002</p></td><td>&nbsp;</td></tr></tbody></table></td><td style="width:119px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>34.3%</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table><p>For the daily composite response, eluxadoline began to separate from placebo shortly after initiating treatment with a maximal effect seen at 4-6 weeks that was maintained throughout the course of treatment. Additionally, the proportion of patients who were composite responders to eluxadoline at each 4-week interval for months 1 through 6 was higher than placebo for both doses in both Phase 3 studies demonstrating that efficacy is maintained with continuous eluxadoline treatment.</p><p>Treatment with eluxadoline also resulted in significant improvements in patients whose IBS-D</p><p>symptoms were not adequately controlled with use of loperamide prior to enrolment.</p><p>When the threshold for abdominal pain response was increased to &ge;40% or &ge;50% improvement from baseline in daily worst abdominal pain, the proportion of abdominal pain responders was 6%-7% higher for eluxadoline 100 mg twice daily compared to placebo which was statistically significant (P &le; 0.009) for the pooled (Study 1 and Study 2) data. Patients receiving eluxadoline also reported significant reductions in bowel movement frequency and abdominal bloating compared to placebo as demonstrated by changes from baseline in daily bowel movements and bloating score at Weeks 12 and</p><p>26. Patients receiving eluxadoline reported significant increases in urgency-free days both for &ge;50% urgency-free days as well as &ge;75% urgency free days. Also, eluxadoline significantly improves patients quality of life as demonstrated by change from baseline score in the IBS-QOL questionnaire at weeks 12 and 26.</p><p>During the 4 week single-blind withdrawal period in Study 2 (IBS-3002), no evidence of rebound diarrhoea or abdominal pain was demonstrated.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has deferred the obligation to submit the results of clinical studies with Viberzi in one or more subsets of the paediatric population in IBS-D (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Eluxadoline&rsquo;s systemic exposure following oral administration is low and is consistent with its local action in the GI tract. The active substance has linear pharmacokinetics with no accumulation upon repeated twice daily dosing. Mean plasma elimination half-life is 5 hours with high inter-subject variability. Eluxadoline is primarily cleared as such via the biliary system with the kidney playing a minimal role in elimination. Eluxadoline is not an inducer/inhibitor of major CYP enzymes, however, eluxadoline has some potential for the metabolism based inactivation of CYP3A4. It is a substrate and an inhibitor of the hepatic uptake transporter OATP1B1; and a substrate for the hepatic efflux transporter MRP2. Hepatic impairment or coadministration with cysclosporine results in significant increases in plasma concentrations of eluxadoline.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>The absolute bioavailability of eluxadoline has not been determined but is estimated to be low due to limited absorption and first pass effects. The absorption of eluxadoline was rapid under fasting conditions, with a median Tmax value of 2 hours. The administration of eluxadoline with a high fat meal significantly decreased both Cmax (50%) and AUC (60%) without any effect on Tmax. Upon administration of multiple oral doses twice daily, there was no accumulation of active substance.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>In a population pharmacokinetic analysis, the estimated apparent volume of distribution of eluxadoline was 27,100 L. In healthy subjects, eluxadoline was moderately (81%) bound to plasma proteins.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Eluxadoline is primarily excreted in the feces, either as unabsorbed active substance or via the biliary system with the kidney playing a minimal role in elimination.</p><p><em>In vitro </em>studies demonstrated that eluxadoline was stable in human hepatocytes, liver and intestinal microsomes, and that the only minor and inactive metabolite of eluxadoline detected was the acyl glucuronide metabolite (M11) formed through glucuronidation of the methoxybenzoic acid moiety. Following a 1,000 mg oral dose in healthy male volunteers, M11 was detected in urine but not in systemic circulation.</p><p>Eluxadoline exists predominantly as the (S,S)-diastereomer (&gt;99%) and undergoes little or no chiral</p><p>conversion <em>in vivo</em>.</p><p>Eluxadoline has a low potential for drug-drug interactions based on limited in vitro CYP inhibition/induction and given that eluxadoline is not a substrate for CYPs at clinically meaningful concentrations.</p><p>&nbsp;</p><p><em>O</em><em>ATP</em><em>1B1 inhibitors</em></p><p>Eluxadoline is a substrate of the hepatic uptake transporter OATP1B1. Co-administration of eluxadoline with cyclosporine (an OATP1B1 inhibitor) increased eluxadoline exposure by approximately 5-fold (see sections 4.3 and 4.5).</p><p>&nbsp;</p><p><em>MRP2 inhibitors</em></p><p>Eluxadoline is a substrate of the hepatic efflux transporter MRP2. Co-administration of eluxadoline with probenecid (MRP2 inhibitor) resulted in approximately 1.4-fold increase in exposure to eluxadoline. No dose adjustment is necessary.</p><p>&nbsp;</p><p><em>O</em><em>ATP1</em><em>B1 substrates</em></p><p>Eluxadoline is an inhibitor of the hepatic uptake transporter OATP1B1. Co-administration of eluxadoline with rosuvastatin (an OATP1B1 substrate) resulted in an up to 1.4-fold increase in exposure of rosuvastatin and the major active metabolite, n-desmethyl rosuvastatin compared to</p><p>administration of rosuvastatin alone. No dose adjustment is necessary for co-administered OATP1B1 substrates. However, caution should be exercised in patients receiving high doses of OATP1B1 substrates (see section 4.5).</p><p>&nbsp;</p><p><em>In vitro assessment of drug interactions</em></p><p><em>In vitro </em>studies indicate that eluxadoline is neither an inducer of CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4, nor an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19,</p><p>CYP2C8 and CYP2D6 at clinically relevant concentrations. CYP2E1 was slightly inhibited (50% inhibitory concentration [IC50] of approximately 20 &micro;M [11 &micro;g/mL]), although this is not expected to result in any clinically meaningful interactions. <em>In vitro </em>studies in liver microsomes showed that eluxadoline is not an inhibitor of CYP3A4 at clinically relevant concentrations, but in intestinal microsomes, eluxadoline inhibited CYP3A4 with a Ki of 450 &micro;M (256 &micro;g/mL). Potentially high (up to 700 &micro;M) eluxadoline concentrations in gut may affect the pharmacokinetic of concomitantly administered CYP3A4 substrates (see section 4.5).</p><p><em>In vitro </em>studies indicated that eluxadoline is a substrate and an inhibitor of the hepatic uptake</p><p>transporter OATP1B1; a substrate for the hepatic efflux transporter MRP2 and is not a substrate or inhibitor of the P-gp and BCRP transporters.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Following a single oral dose of 300 mg [14C] eluxadoline in healthy male subjects, 82.2% of the total [14C] eluxadoline was recovered in faeces in 336 hours and less than 1% was recovered in urine in 192 hours.</p><p>&nbsp;</p><p><u>Specific populations</u></p><p><em>A</em><em>ge and gender</em></p><p>Given eluxadoline&rsquo;s local action in the GI tract, low Foral and lack of metabolism, prospective clinical studies regarding differences in age, body mass index (BMI), ethnicity, and gender were deemed unnecessary. Pharmacokinetic data for healthy volunteers pooled across Phase 1 studies (using the 100 mg single oral dose) and analyzed for potential differences based on sex, age, race, and BMI demonstrated no significant differences.</p><p>&nbsp;</p><p><em>R</em><em>enal Impairment</em></p><p>Eluxadoline has not been specifically studied in patients who have renal impairment. Given the low estimated oral bioavailability (Foral 1.34%) of eluxadoline and limited renal elimination, renal impairment is not expected to affect clearance of eluxadoline.</p><p>&nbsp;</p><p><em>H</em><em>epatic impairment</em></p><p>The apparent clearance of eluxadoline is markedly reduced and half-life increases in hepatic-impaired patients (see sections 4.3 and 4.4). Following single oral 100 mg dose in subjects with varying degrees of liver impairment and healthy subjects, eluxadoline plasma levels were on average 6-fold, 4-fold, and 16-fold elevated in mild, moderate, and severe hepaticimpaired subjects (Child Pugh Class A, B, C), respectively, while half-life increased 3-5 fold (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><em>O</em><em>ATP</em><em>1B1 poor function haplotypes</em></p><p>The plasma levels in patients with a genetic predisposition for poor function of OATP1B1 transporter are increased and in these patients a higher rate of adverse events, especially with regard to gastrointestinal events, as well as CNS effects might be expected (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction and development. In rat, eluxadoline was excreted into milk in an approximately dose proportional manner with maximal concentrations less than plasma concentrations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Silicified microcrystalline cellulose (E460);</p><p>Colloidal anhydrous silica (E551);</p><p>Crospovidone, type B (E1202);</p><p>Mannitol (E421);</p><p>Magnesium stearate (E572);</p><p>Polyvinyl alcohol (E1203);</p><p>Titanium dioxide (E171);</p><p>Macrogol 3350 (E1521);</p><p>Talc (E553b);</p><p>Iron oxide yellow (E172);</p><p>Iron oxide red (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30˚ C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PCTFE/PVC/Al-blister containing 14 film-coated tablets. Pack sizes of 28 film-coated tablets.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Allergan Pharmaceuticals International Limited 
Clonshaugh Industrial Estate
Coolock 
Dublin 17 
Ireland

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>